JP2023542345A - リン酸ヒドロコルチゾンナトリウム及びモノチオグリセロール水性医薬製剤 - Google Patents

リン酸ヒドロコルチゾンナトリウム及びモノチオグリセロール水性医薬製剤 Download PDF

Info

Publication number
JP2023542345A
JP2023542345A JP2023518141A JP2023518141A JP2023542345A JP 2023542345 A JP2023542345 A JP 2023542345A JP 2023518141 A JP2023518141 A JP 2023518141A JP 2023518141 A JP2023518141 A JP 2023518141A JP 2023542345 A JP2023542345 A JP 2023542345A
Authority
JP
Japan
Prior art keywords
sodium phosphate
hydrocortisone sodium
monothioglycerol
impurities
hydrocortisone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542345A5 (cg-RX-API-DMAC7.html
Inventor
チェン，シャオミン
オング，シャオウェイ
Original Assignee
アンタレス・ファーマ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンタレス・ファーマ・インコーポレーテッド filed Critical アンタレス・ファーマ・インコーポレーテッド
Publication of JP2023542345A publication Critical patent/JP2023542345A/ja
Publication of JP2023542345A5 publication Critical patent/JP2023542345A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2023518141A 2020-09-21 2021-09-21 リン酸ヒドロコルチゾンナトリウム及びモノチオグリセロール水性医薬製剤 Pending JP2023542345A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063081164P 2020-09-21 2020-09-21
US63/081,164 2020-09-21
PCT/US2021/051349 WO2022061303A1 (en) 2020-09-21 2021-09-21 Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol

Publications (2)

Publication Number Publication Date
JP2023542345A true JP2023542345A (ja) 2023-10-06
JP2023542345A5 JP2023542345A5 (cg-RX-API-DMAC7.html) 2024-10-01

Family

ID=80775681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518141A Pending JP2023542345A (ja) 2020-09-21 2021-09-21 リン酸ヒドロコルチゾンナトリウム及びモノチオグリセロール水性医薬製剤

Country Status (10)

Country Link
US (3) US20220096496A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213827A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023542345A (cg-RX-API-DMAC7.html)
KR (1) KR20230104131A (cg-RX-API-DMAC7.html)
CN (1) CN116367835A (cg-RX-API-DMAC7.html)
AU (1) AU2021345429A1 (cg-RX-API-DMAC7.html)
CA (1) CA3192530A1 (cg-RX-API-DMAC7.html)
IL (1) IL301352A (cg-RX-API-DMAC7.html)
MX (1) MX2023003197A (cg-RX-API-DMAC7.html)
WO (1) WO2022061303A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540367A (ja) * 2021-11-09 2024-10-31 クロスジェクト 注射デバイス用の薬剤ヒドロコルチゾン溶液

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4496575A4 (en) 2022-03-21 2026-04-01 Antares Pharma Inc AQUEOUS PHARMACEUTICAL FORMULATION OF SODIUM PHOSPHATE, HYDROCORTISONE AND MONOTHIOGLYCEROL
US11904046B1 (en) 2022-11-14 2024-02-20 Eton Pharmaceuticals, Inc. Hydrocortisone oral liquid formulations
WO2024214110A1 (en) * 2023-04-08 2024-10-17 Cipla Limited A safe pharmaceutical composition of hydrocortisone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3696195A (en) * 1969-05-07 1972-10-03 Lepetit Spa Stable aqueous steroid phosphate solutions
JP2019535668A (ja) * 2016-10-26 2019-12-12 クロスジェクト 注射デバイスのための医薬ヒドロコルチゾン溶液

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA911885A (en) * 1972-10-10 Gruppo Lepetit S.P.A. Stable aqueous steroid phosphate solutions
US2970944A (en) 1958-04-04 1961-02-07 Merck & Co Inc Parenteral solutions of steroid phosphates stabilized with creatinines
US5173488A (en) 1989-08-21 1992-12-22 American Cyanamid Company Stable injectable pharmaceutical formulation for folic acid and leucovorin salts and method
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
AU702871B2 (en) * 1993-08-23 1999-03-11 Nexell Therapeutics Inc. (In vitro) growth of neutrophil and megakaryocyte precursors in serum-free media
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
WO2006079064A1 (en) 2005-01-24 2006-07-27 Antares Pharma, Inc. Prefilled needle assisted jet injector
US8067433B2 (en) * 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
ES2548447T3 (es) 2008-03-10 2015-10-16 Antares Pharma, Inc. Dispositivo de seguridad para inyector
US8579865B2 (en) 2009-03-20 2013-11-12 Antares Pharma, Inc. Hazardous agent injection system
WO2014165142A1 (en) 2013-03-13 2014-10-09 Benjamin Newton Multiple dosage injector with rotating screw dosage system
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
EP3189855B1 (en) * 2016-01-11 2018-03-21 Lamda Laboratories S.A. Oral pharmaceutical solutions containing hydrocortisone sodium phosphate
FR3047904B1 (fr) 2016-02-18 2018-03-23 Crossject Dispositif d’injection sans aiguille a membrane coulissante
EP3787671A4 (en) * 2018-05-04 2022-06-15 Ohio State Innovation Foundation NON-PEPTIDE CELL-PENETRATING MOTIFS
US11034710B2 (en) * 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3696195A (en) * 1969-05-07 1972-10-03 Lepetit Spa Stable aqueous steroid phosphate solutions
JP2019535668A (ja) * 2016-10-26 2019-12-12 クロスジェクト 注射デバイスのための医薬ヒドロコルチゾン溶液

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540367A (ja) * 2021-11-09 2024-10-31 クロスジェクト 注射デバイス用の薬剤ヒドロコルチゾン溶液

Also Published As

Publication number Publication date
EP4213827A4 (en) 2024-10-23
US20220096496A1 (en) 2022-03-31
MX2023003197A (es) 2023-08-04
US11857555B2 (en) 2024-01-02
AU2021345429A9 (en) 2024-08-08
KR20230104131A (ko) 2023-07-07
EP4213827A1 (en) 2023-07-26
US20230099165A1 (en) 2023-03-30
WO2022061303A1 (en) 2022-03-24
US20240131035A1 (en) 2024-04-25
AU2021345429A1 (en) 2023-05-04
CA3192530A1 (en) 2022-03-24
IL301352A (en) 2023-05-01
CN116367835A (zh) 2023-06-30

Similar Documents

Publication Publication Date Title
US11857555B2 (en) Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol
US20130116208A1 (en) Administration of a nedd8-activating enzyme inhibitor and hypomethylating agent
US11957736B2 (en) Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
JP6174579B2 (ja) 安定な注射用抗炎症性溶液
US12514907B2 (en) Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes
US20260091042A1 (en) Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol
JP2023052576A (ja) Ｐ２ｙ１２受容体アンタゴニストの皮下投与
RU2860343C2 (ru) Водный фармацевтический состав на основе гидрокортизона натрия фосфата и монотиоглицерина
Pypendop et al. Pharmacokinetics of dexmedetomidine after intravenous administration of a bolus to cats
US20240148678A1 (en) Sustained release injectable therapeutic formulations using aprotic polar solvents
HK40089623A (en) Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol
JP2021502328A (ja) 筋ジストロフィーを治療するためのエダサロネキセント投与計画
BR112021015034B1 (pt) Formulação de anticorpo terapêutico
BR112021015034A2 (pt) Formulação de anticorpo terapêutico
US20160287711A1 (en) Formulation Solution Adapted to Prolong Plasma Times of Drugs in Mammals Including Humans

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240920

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260602